A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400 mg Or 1000 mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy

Next Previous
Trial Profile

A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400 mg Or 1000 mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Tideglusib (Primary)
  • Indications Myotonic dystrophy
  • Focus Adverse reactions; Proof of concept
  • Sponsors AMO Pharma

    • Most Recent Events

    • 15 Mar 2018 According to an AMO Pharma media release, final results from this study were presented at the Muscular Dystrophy Association Conference.
    • 23 Jan 2018 Status changed from active, no longer recruiting to completed.
    • 24 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top